#United States #San Diego #Class Action #Berger Montague #ImmunityBio

Investor Alert: Class Action Suit Against ImmunityBio, Inc.

On April 14, 2026, the prominent law firm Berger Montague LLC announced a class action lawsuit targeting ImmunityBio, Inc. (NASDAQ: IBRX), inviting investors who purchased shares between January 19, 2026, and March 24, 2026, to take action. This move comes amidst serious allegations of securities fraud relating to the company's promising cancer immunotherapy treatments, particularly the Anktiva platform.

Background of the Case

ImmunityBio, based in San Diego, California, is a biopharmaceutical company specializing in the development of innovative therapies for cancer. Recently, concerns have surfaced about possible misleading communications from the company's Chief Scientific and Medical Officer, Patrick Soon-Shiong, regarding Anktiva's performance. Investors are reported to have suffered substantial losses, particularly following revelations that prior statements about the company's operations and future prospects were allegedly exaggerated.

Following the disheartening news, ImmunityBio's stock plummeted by over 21% in a single day, prompting the urgency for investors to find legal recourse. Berger Montague has positioned itself as a strong advocate for affected investors, as it specializes in complex litigation and class action suits.

What Affected Investors Should Know

This class action lawsuit provides a platform for investors who acquired ImmunityBio shares during the specified period to potentially reclaim their losses. Individuals must act quickly; the deadline to seek lead plaintiff status is May 26, 2026. Those interested in pursuing their rights are encouraged to reach out to Andrew Abramowitz or Caitlin Adorni of Berger Montague for further assistance.

Understanding Your Rights

If you were involved in purchasing ImmunityBio securities during the class period, now is your chance to seek justice. Berger Montague has a proven track record of successful class action litigation, having recovered over $50 billion for clients over more than half a century. The firm emphasizes the importance of investors knowing their rights and the available legal options in this developing situation.

Firm Background

With a national presence that spans several major cities, Berger Montague is recognized for its expertise in various areas, including antitrust, consumer protection, and specifically, securities Fraud. The firm prides itself on its commitment to advocating for victims of corporate misconduct and ensuring accountability in public companies. The firm’s experience and stature in the legal field underscore its capability to navigate the complexities of securities law, which is crucial for investors dealing with financial losses in the wake of misleading information.

Conclusion

The ImmunityBio class action lawsuit represents an essential opportunity for impacted investors to seek restitution for their financial losses due to alleged fraudulent practices. With the backing of a reputable and experienced firm like Berger Montague, investors are encouraged to explore their options before the upcoming deadline. For further inquiries, Berger Montague is readily available via direct contact. Don't let this opportunity slip away; take action today to protect your rights as an investor.